Copyright
©The Author(s) 2018.
World J Transplant. Aug 9, 2018; 8(4): 84-96
Published online Aug 9, 2018. doi: 10.5500/wjt.v8.i4.84
Published online Aug 9, 2018. doi: 10.5500/wjt.v8.i4.84
Recommended | Rating | Genotype | Duration |
Recommendations for patients with CKD stage 1, 2 or 3 | |||
No dose adjustment is required when using (1) Daclatasvir (60 mg) (2) Daily fixed-dose combination of elbasvir (50 mg)/grazopevir (100 mg) (3) Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg) (4) Fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) (5) Fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg) (6) Simeprevir (150 mg) (7) Fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)/voxilaprevir (100 mg) (8) Sofosbuvir (400 mg) | I, A | ||
Recommendations for patients with CKD stage 4 or 5 (eGFR < 30 mL/min or ESRD | |||
Daily fixed-dose combination of elbasvir (50 mg)/grazoprevir (100 mg) | I, B | 1a, 1b, 4 | 12 wk |
Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg) | I, B | 1, 2, 3, 4, 5, 6 | 8 to 16 wk |
- Citation: Salvadori M, Tsalouchos A. Hepatitis C and renal transplantation in era of new antiviral agents. World J Transplant 2018; 8(4): 84-96
- URL: https://www.wjgnet.com/2220-3230/full/v8/i4/84.htm
- DOI: https://dx.doi.org/10.5500/wjt.v8.i4.84